多重检测市场 - 全球产业规模、份额、趋势、机会及预测（按产品、类型、技术、应用、最终用户、地区和竞争格局划分），2021-2031年

全球多重检测市场预计将从2025年的32.1亿美元显着成长至2031年的55.4亿美元，复合年增长率（CAGR）达9.52%。多重检测能够在单一检体体积内同时检测和定量多种分析物，是提高诊断效率的先进分析工具。该市场成长的根本驱动力是慢性病发病率的上升以及药物研发中对高通量筛检需求的日益增长。根据美国癌症协会报告，预计2024年美国将新增2,001,140例癌症病例。这项数据凸显了开发可靠的生物标记分析工具以应对日益增长的疾病负担的迫切需求。这正推动着多重检测技术的应用，以简化工作流程并支持精准医疗倡议。

然而，市场扩张面临许多障碍，包括自动化设备所需的大量资本投入以及检测检验相关的技术复杂性。开发这些检测方法需要进行严格的最佳化以降低试剂间的交叉反应，而此过程通常耗时耗力。这些挑战往往会延迟监管核准并增加营运成本，从而限制资源有限的实验室使用和采用多重检测技术。

市场驱动因素

随着製药公司寻求提高研发管线效率，药物研发投入的不断成长正从根本上推动全球多重检测市场的发展。多重检测技术使研究人员能够同时筛检针对多个标靶的化合物，从而加速候选药物的检验和毒性分析。这项投入在产业支出中显而易见，默克公司2023年年度报告显示，该公司将在2023年投入305亿美元用于研发，这显示其在治疗科学领域投入庞大。如此庞大的预算支持采用能够最大限度提高数据输出并降低研发成本的检测方法。生物製程国际（Bioprocess International）报告称，赛默飞世尔科技公司于2024年以约31亿美元收购了Olink，策略性地将可扩展的蛋白质分析技术纳入其产品组合，这进一步印证了该市场的价值。

随着感染疾病的持续蔓延，对能够同时检测多种病原体的诊断工具的需求日益迫切。多重检测对于区分共存感染疾病至关重要，因为它克服了单重检测方法固有的样本量限制。全球卫生统计数据凸显了这一迫切性。根据世界卫生组织（世卫组织）于2024年10月发布的《2024年全球结核病报告》，预计2023年将新增约820万例结核病病例，这将是自监测开始以来的最高数字。日益沉重的负担促使检查室采用高通量解决方案来高效处理检体，而医疗机构也越来越多地转向多重检测平台，以简化工作流程，并在日益严峻的流行病学挑战下确保及时治疗。

市场挑战

阻碍全球多重检测市场成长的主要挑战在于自动化设备所需的高额资本投入以及检测检验的技术复杂性。这些重大的财务和营运障碍直接阻碍了市场扩张，使得多重检测技术的应用仅限于资金雄厚的机构，而资源匮乏的实验室则几乎被排除在外。为防止交叉反应并确保检测可靠性，需要进行严格的优化，这需要大量的时间和预算，从而增加了总体拥有成本 (TCO)。因此，许多诊断实验室被迫依赖传统的低通量方法，阻碍了精准医疗所需的高阶多重检测工作流程的广泛应用。

这些资源负担带来的实际影响体现在近期检查室运作的产业数据。根据美国实验室医学学会 (ADLM) 统计，到 2024 年，48% 的受访临床检查室将停止进行某些检查室自建检测项目，原因是满足日益严格的检验和监管合规标准需要耗费过多的财力和人力资源。这项数据表明，高昂的营运成本和技术检验要求共同迫使检查室缩减检测能力，从而限制了多重检测的整体市场潜力。

市场趋势

能够以高解析度绘製组织微环境内细胞异质性的单细胞多重定序平台正快速改变市场模式。与传统的批量定序（对细胞群体数据进行平均）不同，这些空间生物学技术使研究人员能够在保留样本空间背景的同时，可视化多体学图谱——这对于理解癌症等复杂病理至关重要。这种向空间分析的产业转型得到了大规模整合活动的支持。例如，布鲁克公司在2024年5月的新闻稿中宣布，已完成对NanoString Technologies公司资产的收购，交易金额约为3.926亿美元，旨在加强其在空间转录组学和基因表现分析领域的实力。

同时，照护现场诊断设备的微型化正在推动分散式检查的发展，它将复杂的多重分析功能整合到携带式微流体平台上。这一趋势满足了快速、就近决策的需求，并将诊断模式从集中式高通量检查室转向社区医疗机构。主要诊断设备製造商正积极利用这项转变来扩大分散式检查的部署。为了支持这一战略方向，罗氏在2024年1月的新闻稿中宣布，已达成协议以2.95亿美元收购LumiraDx的照护现场技术平台，其明确目的是将多种免疫检测和临床化学检测集成到单一设备上，用于分散式医疗保健应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球多重检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按产品分类（试剂和耗材、配件和设备、软体和服务）
  • 依类型（核酸、蛋白质、细胞来源）
  • 依技术分类（流式细胞技术、萤光检测、发光法、多重即时即时PCR等）
  • 依应用领域（研发（药物开发、生物标记发现与检验）、临床诊断（感染疾病、癌症、心血管疾病、自体免疫疾病等））
  • 依最终用户（製药/生技公司、医院/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美多重检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲多重检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区多重检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲多重检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲多重检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球多重侦测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Illumina, Inc.
• QIAGEN NV
• Merck KGaA
• Abcam plc
• Becton, Dickinson and Company
• DiaSorin SpA
• Seegene Inc.
• Luminex Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Multiplex Assays Market is projected to expand significantly, growing from USD 3.21 Billion in 2025 to USD 5.54 Billion by 2031, representing a CAGR of 9.52%. Multiplex assays serve as advanced analytical tools that enhance diagnostic efficiency by enabling the simultaneous detection and quantification of multiple analytes within a single sample volume. This market growth is fundamentally underpinned by the increasing prevalence of chronic diseases and the intensified demand for high-throughput screening in drug discovery. As reported by the American Cancer Society, the United States was projected to see 2,001,140 new cancer cases in 2024, a statistic that emphasizes the urgent necessity for robust biomarker profiling tools to manage this escalating disease burden, thereby driving the adoption of multiplexing to streamline workflows and support precision medicine initiatives.

However, market expansion faces substantial obstacles due to the high capital investment required for automated instrumentation and the technical complexity associated with assay validation. Developing these assays necessitates rigorous optimization to mitigate cross-reactivity between reagents, a process that is often both time-consuming and costly. These challenges frequently delay regulatory approval and increase operational expenses, thereby restricting the accessibility and implementation of multiplex technologies within resource-constrained laboratory settings.

Market Driver

Escalating R&D investments in drug discovery are fundamentally driving the Global Multiplex Assays Market, as pharmaceutical companies aim to improve pipeline efficiency. Multiplexing enables researchers to screen compounds against multiple targets simultaneously, which accelerates candidate validation and toxicity profiling. This commitment is evident in industry spending; according to the Merck & Co. Annual Report 2023, the company allocated $30.5 billion to research and development in 2023, demonstrating a significant investment in therapeutic science. Such budgets support the adoption of assays that maximize data output and reduce development costs. Underscoring this market value, BioProcess International reported in 2024 that Thermo Fisher Scientific acquired Olink for approximately $3.1 billion, strategically adding scalable protein analysis to their portfolio.

The increasing prevalence of infectious diseases further creates a critical need for diagnostic tools capable of simultaneous pathogen detection. Multiplex assays are essential for distinguishing co-occurring infections without the sample limitations inherent in singleplex methods. This urgency is highlighted by global health statistics; the World Health Organization's October 2024 'Global Tuberculosis Report 2024' noted that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, the highest figure since monitoring began. This rising burden compels laboratories to utilize high-throughput solutions for efficient sample processing, leading healthcare providers to transition toward multiplex platforms to streamline workflows and ensure timely treatment amidst growing epidemiological challenges.

Market Challenge

A primary challenge impeding the growth of the Global Multiplex Assays Market is the high capital investment required for automated instrumentation alongside the technical complexity of assay validation. These significant financial and operational barriers directly hamper market expansion by restricting the adoption of multiplexing technologies to well-funded institutions, effectively excluding resource-constrained laboratories. The rigorous optimization needed to prevent cross-reactivity and ensure assay reliability demands substantial time and budget, which increases the total cost of ownership. Consequently, many diagnostic facilities are forced to rely on traditional, lower-throughput methods, thereby stalling the widespread implementation of advanced multiplex workflows necessary for precision medicine.

The tangible impact of these resource burdens is reflected in recent industry data regarding laboratory operations. According to the Association for Diagnostics & Laboratory Medicine, in 2024, 48% of surveyed clinical laboratories indicated they would discontinue performing certain laboratory-developed tests due to the prohibitive financial and personnel resources required to meet stricter validation and regulatory compliance standards. This statistic illustrates how the convergence of high operational costs and technical validation requirements directly forces laboratories to scale back their testing capabilities, limiting the overall addressable market for multiplex assays.

Market Trends

The market is being rapidly transformed by the advancement of single-cell multiplexing platforms, which enable high-resolution mapping of cellular heterogeneity within tissue microenvironments. Unlike traditional bulk sequencing that averages data across cell populations, these spatial biology technologies allow researchers to visualize multi-omic profiles while retaining the spatial context of the sample, a capability crucial for understanding complex pathologies like cancer. This industrial pivot toward spatial analysis is validated by significant consolidation activities; for instance, Bruker Corporation announced in a May 2024 press release that it had finalized the acquisition of NanoString Technologies' assets for approximately $392.6 million to strengthen its portfolio in spatial transcriptomics and gene expression analysis.

Simultaneously, the miniaturization of devices for point-of-care diagnostics is driving decentralized testing by integrating complex multiplex capabilities into portable, microfluidic platforms. This trend addresses the need for rapid, near-patient decision-making, shifting the diagnostic paradigm from centralized, high-volume laboratories to community-based settings. Major diagnostic leaders are actively capitalizing on this shift to expand their decentralized testing footprints. Validating this strategic direction, Roche announced in a January 2024 press release its agreement to acquire LumiraDx's point-of-care technology platform for a purchase price of $295 million, explicitly to integrate multiple immunoassay and clinical chemistry tests onto a single instrument for decentralized healthcare use.

Key Market Players

• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Illumina, Inc.
• QIAGEN N.V.
• Merck KGaA
• Abcam plc
• Becton, Dickinson and Company
• DiaSorin S.p.A.
• Seegene Inc.
• Luminex Corporation

Report Scope

In this report, the Global Multiplex Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multiplex Assays Market, By Product

• Reagents & Consumables
• Accessories & Instruments
• Software & Services

Multiplex Assays Market, By Type

• Nucleic Acid
• Protein
• Cell-based

Multiplex Assays Market, By Technology

• Flow Cytometry
• Fluorescence Detection
• Luminescence
• Multiplex Real-Time PCR
• Others

Multiplex Assays Market, By Application

• Research & Development (Drug Development)
• Biomarker Discovery & Validation
• Clinical Diagnosis (Infectious Disease)
• Cancer
• Cardiovascular Disease
• Autoimmune Disease
• Others

Multiplex Assays Market, By End User

• Pharmaceutical & Biotechnology Companies
• Hospitals & Research Institutes
• Others

Multiplex Assays Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multiplex Assays Market.

Available Customizations:

Global Multiplex Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Multiplex Assays Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Reagents & Consumables, Accessories & Instruments, Software & Services)
  • 5.2.2. By Type (Nucleic Acid, Protein, Cell-based)
  • 5.2.3. By Technology (Flow Cytometry, Fluorescence Detection, Luminescence, Multiplex Real-Time PCR, Others)
  • 5.2.4. By Application (Research & Development (Drug Development, Biomarker Discovery & Validation), Clinical Diagnosis (Infectious Disease, Cancer, Cardiovascular Disease, Autoimmune Disease, Others))
  • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Multiplex Assays Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Type
  • 6.2.3. By Technology
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multiplex Assays Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Multiplex Assays Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Multiplex Assays Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Multiplex Assays Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Type
  • 7.2.3. By Technology
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Multiplex Assays Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Multiplex Assays Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Multiplex Assays Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Multiplex Assays Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Multiplex Assays Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia Pacific Multiplex Assays Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Type
  • 8.2.3. By Technology
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Multiplex Assays Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Multiplex Assays Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Multiplex Assays Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Multiplex Assays Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Multiplex Assays Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. Middle East & Africa Multiplex Assays Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Type
  • 9.2.3. By Technology
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Multiplex Assays Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Multiplex Assays Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Multiplex Assays Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. South America Multiplex Assays Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Type
  • 10.2.3. By Technology
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Multiplex Assays Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Multiplex Assays Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Multiplex Assays Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Multiplex Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bio-Rad Laboratories
• 15.3. Illumina, Inc.
• 15.4. QIAGEN N.V.
• 15.5. Merck KGaA
• 15.6. Abcam plc
• 15.7. Becton, Dickinson and Company
• 15.8. DiaSorin S.p.A.
• 15.9. Seegene Inc.
• 15.10. Luminex Corporation

16. Strategic Recommendations

17. About Us & Disclaimer